Skip to main content

Table 2 Univariable and multivariable analyses of the first-line response to chemotherapy

From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Variables Tumor response Univariable Analysis Multivariable analysis
CR + PR SD + PD ORR OR (95% CI) p value OR (95% CI) p value
Age (years)      0.042*   0.251
  ≤ 65 57 38 60.0% Ref.   Ref.  
 >65 23 31 42.6% 0.495 (0.251–0.974)   0.593 (0.243–1.447)  
Sex      0.177   
 Male 56 55 50.5% 0.594 (0.279–1.266)    
 Female 24 14 63.2% Ref.    
Smoking      0.550   
 Never 34 26 56.7% Ref.    
 Ever 46 43 51.7% 0.818 (0.423–1.580)    
ECOG PS      0.001**   0.302
 0 49 24 67.1% Ref.   Ref.  
 1 31 45 40.8% 0.337 (0.173–0.659)   0.646 (0.282–1.481)  
Lesion type      0.344   
 Peripheral 41 30 57.7% Ref.    
 Central 39 39 50.0% 0.732 (0.383–1.398)    
Histological type      0.857   
 Adenocarcinoma 51 43 54.3% Ref.    
 Squamous 29 26 52.7% 0.940 (0.483–1.832)    
Clinical stage      0.004**   0.008**
 IIIB 46 23 66.7% Ref.   Ref.  
 IV 34 46 42.5% 0.370 (0.189–0.721)   0.283 (0.112–0.718)  
CEA      0.042*   0.170
 Normal 57 38 60.0% Ref.   Ref.  
 Increased 23 31 42.6% 0.495 (0.251–0.974)   0.539 (0.223–1.303)  
Albumin      0.093   
 Decreased 22 28 44.0% 0.555 (0.279–1.104)    
 Normal 58 41 58.6% Ref.    
WBC(×109/L)      0.003**   0.424
  ≤ 7.8 53 29 64.6% Ref.   Ref.  
 >7.8 27 40 40.3% 0.369 (0.190–0.719)   0.710 (0.307–1.644)  
LMR      < 0.001***   < 0.001***
  ≤ 3.73 32 57 36.0% 0.140 (0.065–0.302)   0.167 (0.062–0.454)  
 >3.73 48 12 80.0% Ref.   Ref.  
NLR      0.009**   0.737
  ≤ 2.67 45 24 65.2% Ref.   Ref.  
 >2.67 35 45 43.8% 0.415 (0.214–0.806)   1.176 (0.456–3.032)  
PLR      0.084   
  ≤ 164 54 37 59.3% Ref.    
 >164 26 32 44.8% 0.557 (0.286–1.083)    
SUVmax      < 0.001***   0.001**
  ≤ 11.6 50 19 72.5% Ref.   Ref.  
 >11.6 30 50 37.5% 0.228 (0.114–0.457)   0.217 (0.090–0.525)  
  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, CEA carcinoembryonic antigen, WBC white blood cell, LMR lymphocyte-monocyte ratio, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, SUVmax maximum standardized uptake value, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, OR odds ratio, CI confidence interval. *, p < 0.05; **, p < 0.01; ***, p < 0.001